{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Zim Laboratories Ltd is Rated Strong Sell
Zim Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 August 2025. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 05 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.
Zim Laboratories Ltd is Rated Strong Sell
Zim Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 August 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 January 2026, providing investors with the latest insights into its performance and outlook.
Zim Laboratories Ltd is Rated Strong Sell
Zim Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 August 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 14 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Zim Laboratories Ltd Stock Hits 52-Week Low Amidst Continued Financial Pressures
Zim Laboratories Ltd has touched a new 52-week low of Rs.64.1 today, marking a significant decline in its stock price amid ongoing financial pressures and subdued performance metrics. Despite a modest recovery over the past two days, the stock remains considerably below its previous highs and continues to trail behind sector benchmarks.
Zim Laboratories Ltd is Rated Strong Sell
Zim Laboratories Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 08 August 2025, reflecting a shift from the previous 'Sell' grade. However, the analysis and financial metrics discussed below represent the stock's current position as of 03 January 2026, providing investors with the latest insights into the company’s performance and outlook.
Why is Zim Laboratories Ltd falling/rising?
On 26-Dec, Zim Laboratories Ltd witnessed a notable decline in its share price, closing at ₹67.65, down ₹2.55 or 3.63% from the previous session. This movement reflects ongoing challenges for the stock, which has underperformed both its sector and the broader market benchmarks over multiple timeframes.
Zim Laboratories Sees Revision in Market Evaluation Amidst Challenging Fundamentals
Zim Laboratories, a microcap player in the Pharmaceuticals & Biotechnology sector, has undergone a revision in its market evaluation metrics reflecting ongoing challenges in its financial and operational performance. This shift highlights the company’s current standing amid a backdrop of subdued profitability and persistent negative results.
Zim Laboratories Sees Revision in Market Assessment Amidst Challenging Fundamentals
Zim Laboratories, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting ongoing challenges in its financial and technical outlook. The stock has faced persistent headwinds, with recent assessment changes highlighting concerns across multiple performance parameters.
Zim Laboratories Faces Intense Selling Pressure Amid Consecutive Losses
Zim Laboratories, a key player in the Pharmaceuticals & Biotechnology sector, is currently experiencing severe selling pressure with no buyers in the queue, signalling distress selling and a challenging market environment for the stock.
Zim Laboratories Faces Selling Pressure with Year-to-Date Losses of 31.56% Amid Declines
Zim Laboratories Ltd is experiencing significant selling pressure, marked by consecutive days of losses. While it has shown a modest weekly gain, its longer-term performance is troubling, with notable declines over three months, year-to-date, and the past year, reflecting broader market trends and potential company-specific challenges.
Zim Laboratories Faces Financial Challenges Amidst Mixed Market Performance Trends
Zim Laboratories has reported a challenging financial quarter ending September 2025, with significant declines in profit before tax and profit after tax. Key metrics show low return on capital employed and reduced cash reserves, alongside a rising debt-equity ratio, indicating heightened financial concerns amid mixed market performance.
Zim Laboratories Q2 FY26: Losses Deepen Amid Revenue Recovery
Zim Laboratories Ltd., a Nagpur-based pharmaceutical formulations manufacturer, reported a net loss of ₹0.42 crores for Q2 FY26, marking a sharp deterioration from the previous quarter's loss of ₹1.87 crores and reversing the profit of ₹2.38 crores recorded in Q2 FY25. The company, with a market capitalisation of ₹354.00 crores, saw its stock trading at ₹74.33 on November 14, 2025, down 31.11% over the past year despite a modest 1.79% gain on the day.
How has been the historical performance of Zim Laboratories?
Zim Laboratories' historical performance shows fluctuating financial metrics, with net sales at 379.03 Cr in March 2025, a slight increase from the previous year but a decrease from March 2023. Key figures include a rise in operating profit to 49.50 Cr, while profit before tax and profit after tax fell to 18.01 Cr and 12.17 Cr, respectively.
Why is Zim Laboratories falling/rising?
As of 13-Nov, Zim Laboratories Ltd's stock price is Rs 72.67, down 5.5%, with a year-to-date decline of 32.08%. Despite a recent short-term gain of 2.60%, the stock has significantly underperformed over the long term, dropping 76.82% in three years compared to the Sensex's growth.
How has been the historical performance of Zim Laboratories?
Zim Laboratories has shown mixed historical performance, with net sales increasing slightly to 379.03 Cr in March 2025 but declining in profitability, with profit after tax dropping to 12.17 Cr. While total assets rose, cash flow management remains a challenge, with a net cash outflow of -7.00 Cr in March 2025.
Why is Zim Laboratories falling/rising?
As of 11-Nov, Zim Laboratories Ltd's stock price is at 77.62, up 10.15% today, but down 27.46% year-to-date. While it has outperformed the Sensex recently, its long-term performance remains weak.
Zim Laboratories Ltd Sees 0.63% Gain Today Amid Broader Market Decline, Still Down 34.33% YTD
Zim Laboratories Ltd is experiencing increased buying activity, showing a slight gain today while the Sensex declines. Despite this, the stock has faced recent losses and significant declines over the past year, remaining below key moving averages, indicating ongoing challenges in its market position.
Zim Laboratories Faces Significant Selling Pressure with 36.46% Yearly Loss and Persistent Decline
Zim Laboratories Ltd is experiencing significant selling pressure, continuing a trend of consecutive losses. The stock has underperformed compared to the Sensex over various time frames, with notable declines over the past year and three years. It is also trading below multiple moving averages, indicating ongoing challenges.
Why is Zim Laboratories falling/rising?
As of 30-Oct, Zim Laboratories Ltd's stock price is Rs 74.37, down 10.11% and significantly underperforming its sector. Despite increased investor participation, the stock has declined 30.79% over the past year, contrasting with the Sensex's 5.58% gain.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
